Today (23 May), the ABPI and the AHSN Network publish a new guide to cross-sector working between NHS Sustainable Transformation Partnerships (STPs), Integrated Care Systems (ICSs) and industry. The guide sets out governance and process recommendations to make collaboration more straightforward.
Life sciences is among a select group of highly innovative industries linked to science and tech which could be responsible for a new wave of growth worth an extra £14 billion a year to the UK economy by 2025.
Haseeb Ahmad, Managing Director, UK, Ireland & Nordics Novartis Pharmaceuticals and Country President Novartis UK has been confirmed as the new President of the ABPI.
The Government will today announce at the ABPI Conference that the most promising treatments will be fast-tracked by the new and boosted Accelerated Access Collaborative. Medicines, technologies and diagnostic tools targeting key health problems will be prioritised. The ABPI welcomes the move.
The ABPI responded to Radio 4's File on Four programme on opioids, which examined whether there are any similarities between the way in which opioid medications are being marketed by pharmaceutical companies in the US and the UK.
Health Secretary Matt Hancock has announced that all opioid medicines in the UK will carry prominent warnings on the labels saying they can cause addiction.
In light of the Government's announcement of an extension to article 50, ABPI commented on the position regarding stockpiling of medicines in preparation for a 'no-deal'.
The Department of Health and Social Care today published the 2019 update of their Implementation Plan for England for the UK Strategy for Rare Diseases. This sets out progress made against the original commitments in the Strategy.
King’s College London, Wellcome and pharmaceutical company MSD announced a collaboration and licencing deal today that could lead to a new class of pain medications.
“Pharmaceutical companies have done everything in their power to prepare for a ‘no deal’ Brexit. This includes increasing stocks of medicines, changing and adding new supply routes and duplicating manufacturing processes here and in Europe." MORE >